Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Emerging Therapies in Multiple Myeloma

October 15th 2015

Clinical Experience With Panobinostat in Multiple Myeloma

October 15th 2015

Triplet Therapy for Relapsed/Refractory Multiple Myeloma

October 15th 2015

HDAC Inhibitors in Multiple Myeloma

October 15th 2015

Integrating Agents in Relapsed/Refractory Multiple Myeloma

October 15th 2015

Treating Double-Refractory Multiple Myeloma

October 15th 2015

Therapeutic Sequencing in Multiple Myeloma

October 15th 2015

Third-Line Options for Multiple Myeloma

October 15th 2015

Treatment Approaches for Relapsed/Refractory Multiple Myeloma

October 15th 2015

Pathogenesis of Multiple Myeloma

October 15th 2015

Experts Share Hopes for the Future of Myeloma Treatment

October 14th 2015

The data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.

Dr. Kumar on Defining Multiple Myeloma

October 12th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

Expert Optimistic About Achieving Cure for Myeloma

September 29th 2015

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents.

Carfilzomib Granted Priority Review for Relapsed Multiple Myeloma

September 18th 2015

The FDA has granted a priority review designation to carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

Three Priority Review Designations, Zarxio Now Available, Rolapitant Approved, and More

September 11th 2015

FDA Grants Ixazomib Priority Review in Multiple Myeloma

September 9th 2015

The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.

FDA Grants Priority Review to Daratumumab in Multiple Myeloma

September 4th 2015

The FDA has assigned a priority review designation to daratumumab for heavily pretreated patients with multiple myeloma.

Panobinostat Approved in Europe for Multiple Myeloma

September 4th 2015

The European Commission has approved panobinostat in combination with bortezomib and dexamethasone for adult patients with relapsed/refractory multiple myeloma following prior treatment with bortezomib and an immunomodulatory agent.

Dr. Sarah Holstein on Lenalidomide Maintenance Updates

September 1st 2015

Sarah Holstein, MD, PhD, Assistant Professor of Oncology, Lymphoma/Myeloma Service Department of Medicine, Roswell Park Cancer Institute, discusses an updated of analysis CALGB/ECOG/BMT CTN 100104, which investigated lenalidomide maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma.

FDA Grants Elotuzumab Priority Review in Multiple Myeloma

September 1st 2015

The FDA has granted elotuzumab (Empliciti) a priority review for use in combination therapy in pretreated patients with multiple myeloma.